More answers like this
GPT-5Nov 3, 2026openai/gpt-5-2025-08-07
Should AI development be paused or restricted?
Short answer: Yes—some AI development should be restricted, and in a few areas temporarily paused— but not via a blanket halt. The safest approach is targeted, capability-based controls with clear “go/no-go” gates.
A practical framework
•Scope the rules by risk, not by label. Focus on models or systems that show dangerous capabilities (e.g., enabling biological misuse, scalable cyber offense, autonomous replication/manipulation, or high-fidelity deception/persuasion). Leave low-risk and clearly beneficial work largely unencumbered.
•Require a safety case before training frontier models. For runs above specified compute/capability thresholds, labs should secure a license that demonstrates governance, red-teaming capacity, model security, incident response, and post-deployment monitoring. If the safety case can’t be met, pause that run until it can.
•Mandate pre-deployment evaluations. Independent evals for bio/cyber/autonomy/persuasion risks; stress tests against misuse; robustness/transfer testing; and clear release notes about limitations and residual risks.
•Apply graduated deployment controls. Rate limits, tool access gating, identity verification for high‑risk API features, strong default guardrails, and rapid kill switches for emergent harms.
•Protect model weights and tools. Hardened security, secrets management, and staged or delayed release of weights for highly capable models; prefer hosted access with oversight over open release when hazard scores are high.
•Track and govern compute. Reporting of large training runs, KYC for access to very large cloud GPU clusters, and hardware-level telemetry to make extreme-scale training auditable.
•Transparency and accountability. Incident reporting, third‑party audits, liability/insurance for high‑risk deployments, and clear provenance of AI-generated content.
•Differential development. Prioritize funding and fast-tracking for safety research (evals, interpretability, alignment, robust/secure training) even when capability work is paused.
•International coordination. Harmonize thresholds and audits, close loopholes in export controls for high‑end chips, and share best practices to avoid a weakest‑link problem.
•Sunsets and updates. Rules should have review dates, with thresholds adjusted as evidence improves.
When to pause
•Temporarily pause training or release of a system if evals cross agreed risk thresholds and mitigations are unproven.
•Pause weight releases (but allow controlled API access) when open weights would materially lower the barrier to serious misuse.
•Pause autonomous agent features that can operate without tight human oversight in real‑world environments until reliability and containment are demonstrated.
What not to pause
•Safety, alignment, and security research.
•Narrow, low‑risk applications with clear social benefit and strong domain oversight (e.g., radiology decision support with clinical supervision).
•Tooling and governance infrastructure (auditing, red‑teaming, provenance standards).
Pros of targeted restrictions
•Reduces tail risks while preserving most benefits.
•More enforceable than a blanket moratorium.
•Encourages a “safety case before scale” culture.
Cons and trade‑offs
•Risk of regulatory capture if thresholds or licenses are poorly designed.
•Global coordination and enforcement are hard.
•Slows some innovation and may shift activity to less regulated jurisdictions.
If you share your role (policymaker, researcher, founder, engineer, citizen advocate), I can tailor concrete steps and example policies you can use tomorrow.